We launched Fulcrum Therapeutics with a bold vision: To change the course of genetically defined diseases by treating
them at their root cause.
Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively
about the best way to modulate and balance gene expression. The result: FulcrumSeek, a patient-focused product
engine designed to systematically identify high-value, de-risked targets at speed and scale for rare genetic
diseases. We take great pride in being purposeful patient partners who do this work, not just for patients,
but with patients. We have a culture of trust and transparency which enables our employees to focus on our mission and
the science behind it. In addition, we are invested in our people and want to ensure they have the tools and training
they need to succeed. This allows our playful spirit to come alive, making work more enjoyable for our entire Fulcrew.
Alex C. Sapir
Alex C. Sapir is an industry veteran and organization builder with over two decades of experience in the biopharmaceutical industry, most recently serving as CEO of ReViral Ltd, which was acquired in 2022 by Pfizer. Previously, he served as president and CEO at Dova Pharmaceuticals, leading its transformation from a small, private, pre-commercial company to a 150-person, fully integrated, publicly traded biotech company (later acquired by Sobi, Inc.).
Earlier in his career, Alex was the Executive Vice President for Marketing and Sales at United Therapeutics and held commercial positions of increasing responsibility at GSK and other smaller healthcare companies.
Alex received his BA in Economics from Franklin and Marshall College and his MBA from Harvard Business School where he concentrated in Finance and Strategy.
Jeff Jacobs, Ph.D.
Dr. Jacobs has more than 25 years of experience in drug discovery and target identification, and has led, co-led and mentored multiple discovery programs from concept stage through development candidate nomination, and from investigational new drug enabling studies through to pivotal clinical trials. Dr. Jacobs was most recently Chief Scientific Officer at Goldfinch Bio, where he led the research and discovery program to help build its portfolio of therapeutics for rare kidney diseases. Before Goldfinch, Dr. Jacobs held roles of increasing responsibilities at Ardelyx, Inc., and was promoted to Chief Scientific Officer. During his time at Ardelyx, he led the discovery effort for IBSRELA®, an oral small molecule for the treatment of irritable bowel syndrome with constipation, that became its first U.S. Food and Drug Administration (FDA) approved product. Earlier, Dr. Jacobs held senior roles in development chemistry at Sunesis Pharmaceuticals, along with similar roles leading chemistry teams at Versicor, Inc. (acquired by Pfizer), and Affymax (acquired by Glaxo Wellcome). Dr. Jacobs earned a Ph.D. in bioorganic chemistry from the University of California, Berkeley and a B.S. in chemistry from Gonzaga University.
Mel joined Fulcrum in September 2021 as Chief Commercial Officer and was subsequently appointed to the role of Chief Operating Officer in June 2022. Mel has responsibility for corporate strategy and operations, in addition to commercial. Mel brings more than 25 years of experience in asset development and management of commercialization strategies in a range of therapeutic areas including many rare, specialty and primary care diseases. Prior to Fulcrum, Mel served as Global Head Commercial, Vice President, Rare Blood Disorders at Sanofi-Genzyme, where he led the commercial organization for hemophilia and complement assets. His previous roles also include U.S. Vice President, Hemophilia and Global Head, Hematology Rare Blood Disorders at Bioverativ (acquired by Sanofi-Genzyme) and Global Vice President, Head of Global Marketing and Launch Excellence at Shire and Global Vice President, Hemophilia at Baxalta (acquired by Shire). He also spent 10 years at Bayer and nine years at Bristol Myers Squibb in progressive leadership roles where he was responsible for launching products in diabetes, cardiovascular disease, neurology, rheumatology, multiple sclerosis, and Parkinson’s disease globally.
Mel earned dual bachelor’s degrees in business and communications from Southern Methodist University and received his MBA from Columbia University.
Alan joined Fulcrum in August 2023 as Chief Financial Officer. Prior to joining Fulcrum, Alan served for several years as CFO of ReViral, which was acquired by Pfizer in 2022. Previously, he was the Chief Financial Officer and Treasurer at Peloton Therapeutics Inc., where he secured a $150 million mezzanine financing and prepared the company for a NASDAQ IPO until the company was acquired by Merck & Co. Alan also served as CFO and Treasurer of other biopharmaceutical companies, including Bellicum Pharmaceuticals, Targacept, and Duramed Pharmaceuticals. He spent the early part of his career as a senior internal auditor for Pfizer as well as a Certified Public Accountant (CPA) for KPMG International.
Alan received a B.S. in Accounting from Saint Mary’s College California and a master’s degree from the American Graduate School of International Management. He currently serves on the Board of Directors for Lung Therapeutics, Inc.
Curtis Oltmans, JD
Curtis Oltmans, JD, joined Fulcrum as General Counsel in November 2020 with over 25 years of experience in corporate law, including senior management positions in legal departments at several leading pharmaceutical and biotechnology companies. He most recently served as Vice President, Head of Litigation at DaVita Kidney Care, Inc., where he led a 30-person team and was responsible for all litigation, workers’ compensation, and employee safety matters. Before DaVita, Curtis was Executive Vice President, General Counsel, and Corporate Secretary at Array BioPharma Inc., overseeing all legal, corporate governance, patent, and compliance matters. He previously served as Corporate Vice President and General Counsel for Novo Nordisk, Inc., North America, where he was responsible for strategic support in areas including market access, government affairs, communications, and product marketing. He has also served as Assistant General Counsel for Eli Lilly and Company after beginning his legal career, supporting clients in pharmaceutical and medical device litigation matters.
Curtis received a BA in political science from the University of Nebraska and his JD from the University of Nebraska College of Law.
Mani Sundararajan, Ph.D.
Paul Bruno, Ph.D.
Paul Bruno, Ph.D., was named Senior Vice President, Business and Corporate Development in August 2022, bringing experience in business development, corporate development, strategic consulting, and R&D. He joined Fulcrum in 2019 where he has held various roles related to business and corporate development. He was previously at ClearView Healthcare Partners, a life sciences strategy firm that specializes in working with biotech, pharma, and medtech companies. At ClearView, Paul worked with clients on corporate strategy, portfolio management, pipeline prioritization, and business development engagements. Paul completed a postdoctoral fellowship at Boston Children’s Hospital, where he focused on identifying fetal hemoglobin inducers for sickle cell disease and β-thalassemia. He also brings entrepreneurial experience, having previously co-founded and raised seed funding for an early-stage materials company.
He received his Ph.D. in chemistry from the University of Michigan and a BS from Santa Clara University, where he double majored in chemistry and public health.
Kristina Storey joined Fulcrum in November 2022 as senior vice president, head of regulatory affairs and quality assurance. Kristina brings over two decades of experience maximizing the value of complex clinical programs and leading successful global regulatory interactions across multiple therapeutic areas.
Most recently, Kristina was vice president of regulatory affairs at Pharvaris, a clinical-stage biopharmaceutical company focused on advancing small-molecule alternatives for patients with hereditary angioedema and other bradykinin B2-receptor-mediated indications. Prior to that she held roles of increasing responsibility at Momenta Pharmaceuticals and served as the vice president and head of regulatory affairs at the time of its acquisition by Johnson & Johnson.
Kristina holds a Regulatory Affairs Certification and received a Bachelor of Arts degree from the University of New Hampshire.
Iain Fraser, MBChB, D.Phil was appointed interim chief medical officer in March 2023. Dr. Fraser brings over two decades of experience advancing therapies through early- and late-stage development and possesses deep expertise in clinical development and regulatory affairs. He most recently served as vice president and clinical fellow atAlloVir, an Elevate Bio Company.
He previously held clinical development roles of increasing responsibility at Abide Therapeutics (acquired by Lundbeck in 2019) and Merck, where he led the first-in-human clinical trials of a range of compounds across therapeutic areas, and contributed to the development of Zepatier®, Zinplava™ and Recarbrio™, as well as the pediatric development of Januvia® and Maxalt®.
He received a Master of Science in Clinical Investigation from Harvard University and a Doctor of Philosophy in Experimental Pathology from the University of Oxford. Dr. Fraser received his Bachelor of Science in Biochemistry as well as his Bachelor of Medicine, Bachelor of Surgery – MBChB from the University of Cape Town.